- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Canadian firm to sell mammography CAD
A Canadian biotechnology company is negotiating for rights to market a mammography computer-aided diagnosis (CAD) workstation under development in the U.S. The workstation is scheduled to be introduced as a work-in-progress at this year's Radiological
A Canadian biotechnology company is negotiating for rights to market a mammography computer-aided diagnosis (CAD) workstation under development in the U.S. The workstation is scheduled to be introduced as a work-in-progress at this year's Radiological Society of North America meeting.
Qualia Computing of Beavercreek, OH, is developing the workstation, called CADx. The system is designed to provide a backup to mammographers by identifying microcalcifications and suspicious images. CADx employs image enhancement techniques and neural network software. Many of the Qualia engineers working on the project have experience developing pattern recognition systems for the U.S. Air Force Institute of Technology (AFIT) at Wright Patterson Air Force Base in Dayton, OH.
Qualia has reached an agreement-in-principle to license exclusive rights to CADx to Briana Bio-Tech of Edmonton, Alberta. Briana has agreed to fund development of CADx and provide royalty and milestone payments.
When the workstation reaches the market, it could become a competitor to systems being developed by firms such as Scanis of Mountain View, CA, and R2 Technology of Los Altos, CA. R2 began European sales of its ImageChecker system earlier this year (SCAN 4/16/97).
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
